Literature DB >> 18644632

Reflections on the "intrathymic pathogenesis" of myasthenia gravis.

Reinhard Hohlfeld1, Hartmut Wekerle.   

Abstract

The beneficial effects of thymectomy argue for a causal role of the thymus in myasthenia gravis (MG). The MG thymus contains acetylcholine receptor (AChR), which is expressed by myoid cells (whole AChR), and by medullary thymic epithelial cells (AChR subunits). The myoid cells are closely associated with antigen-presenting dendritic cells, helper T cells, and antibody-producing B cells in lymphoid follicles ("lymphofollicular hyperplasia"). Thus, all the cellular components required to initiate and maintain an autoimmune response to AChR are present in the MG thymus. It is unlikely that the cellular alterations in the thymus are secondary to an ongoing peripheral immune response, because they are absent in experimental autoimmune myasthenia gravis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18644632     DOI: 10.1016/j.jneuroim.2008.05.020

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  9 in total

Review 1.  [True thymic hyperplasia : Differential diagnosis of thymic mass lesions in neonates and children].

Authors:  C-A Weis; B Märkl; T Schuster; K Vollert; P Ströbel; A Marx
Journal:  Pathologe       Date:  2017-07       Impact factor: 1.011

2.  Intrathymic Tfh/B Cells Interaction Leads to Ectopic GCs Formation and Anti-AChR Antibody Production: Central Role in Triggering MG Occurrence.

Authors:  Xiaoyan Zhang; Shasha Liu; Ting Chang; Jiang Xu; Chunmei Zhang; Feng Tian; Yuanjie Sun; Chaojun Song; Wei Yi; Hong Lin; Zhuyi Li; Kun Yang
Journal:  Mol Neurobiol       Date:  2014-11-19       Impact factor: 5.590

3.  The molecular anatomy of human Hsp60 and its similarity with that of bacterial orthologs and acetylcholine receptor reveal a potential pathogenetic role of anti-chaperonin immunity in myasthenia gravis.

Authors:  Antonella Marino Gammazza; Fabio Bucchieri; Luigi M E Grimaldi; Arcangelo Benigno; Everly Conway de Macario; Alberto J L Macario; Giovanni Zummo; Francesco Cappello
Journal:  Cell Mol Neurobiol       Date:  2012-01-19       Impact factor: 5.046

4.  Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature.

Authors:  Bettina Schreiner; Burkhard Becher; Florian Ingelfinger; Sinduya Krishnarajah; Michael Kramer; Sebastian G Utz; Edoardo Galli; Mirjam Lutz; Pascale Zwicky; Ayse U Akarca; Nicole Puertas Jurado; Can Ulutekin; David Bamert; Corinne C Widmer; Luca Piccoli; Federica Sallusto; Nicolás G Núñez; Teresa Marafioti; Didier Schneiter; Isabelle Opitz; Antonio Lanzavecchia; Hans H Jung; Donatella De Feo; Sarah Mundt
Journal:  Acta Neuropathol       Date:  2021-03-28       Impact factor: 17.088

5.  B-cell-activating factor and autoimmune myasthenia gravis.

Authors:  Samia Ragheb; Robert P Lisak
Journal:  Autoimmune Dis       Date:  2011-11-28

6.  Membranous nephropathy, leiomyoma and autoimmune myasthenia: more than a coincidence?

Authors:  Jesus Calviño; Magdalena Adeva; Maria-Jesus Sobrido
Journal:  Clin Kidney J       Date:  2012-11-07

Review 7.  Thymus and autoimmunity.

Authors:  Alexander Marx; Yosuke Yamada; Katja Simon-Keller; Berthold Schalke; Nick Willcox; Philipp Ströbel; Cleo-Aron Weis
Journal:  Semin Immunopathol       Date:  2021-02-03       Impact factor: 9.623

8.  Expression of RAGE and HMGB1 in thymic epithelial tumors, thymic hyperplasia and regular thymic morphology.

Authors:  Bernhard Moser; Stefan Janik; Ana-Iris Schiefer; Leonhard Müllauer; Christine Bekos; Anke Scharrer; Michael Mildner; Ferenc Rényi-Vámos; Walter Klepetko; Hendrik Jan Ankersmit
Journal:  PLoS One       Date:  2014-04-04       Impact factor: 3.240

Review 9.  [The value of thymectomy in the treatment of non-thymomatous myasthenia gravis].

Authors:  Hruy Menghesha; Michael Schroeter; Fabian Doerr; Georg Schlachtenberger; Matthias B Heldwein; Costanza Chiapponi; Thorsten Wahlers; Christiane Bruns; Khosro Hekmat
Journal:  Chirurg       Date:  2021-06-16       Impact factor: 0.955

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.